Galecto, Inc.

Galecto, Inc.

Forskning inden for bioteknologi

Copenhagen, DK 4.197 følgere

Clinical stage fibrosis and cancer treatments

Om os

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Branche
Forskning inden for bioteknologi
Virksomhedsstørrelse
11-50 medarbejdere
Hovedkvarter
Copenhagen, DK
Type
Privat
Grundlagt
2011
Specialer
Galectin modulators, Galectin-3 inhibitors, Fibrosis treatment, LOXL2, Inflammation, Oncology, IPF, Liver fibrosis og Myelofibrosis

Beliggenheder

  • Ole Maaloes Vej 3

    Cobis Science Park

    Copenhagen, DK DK-2200, DK

    Se ruten

Medarbejdere hos Galecto, Inc.

Opdateringer

Tilsvarende sider

Finansiering

Galecto, Inc. 4 runder i alt

Seneste runde

Serie D

64.000.000,00 US$

Læs mere på crunchbase